Impact of malignancy on Clostridium difficile infection
- Authors
- Chung, Min Sung; Kim, Ji eun; Kang, Jung Oak; Pai, Hyunjoo
- Issue Date
- Nov-2016
- Publisher
- SPRINGER
- Citation
- EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, v.35, no.11, pp.1771 - 1776
- Indexed
- SCIE
SCOPUS
- Journal Title
- EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Volume
- 35
- Number
- 11
- Start Page
- 1771
- End Page
- 1776
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5488
- DOI
- 10.1007/s10096-016-2725-6
- ISSN
- 0934-9723
- Abstract
- Purpose
The purpose of this study was to investigate the impact of malignancy and chemotherapy on the clinical and microbiological characteristics of Clostridium difficile infections (CDI).
Methods
CDI patients with a history of malignancy within 5 years were defined as the cancer group. The characteristics of the patients were compared according to the presence of malignancy.
Results
Of 580 patients with CDI, 159 (27.4 %) belonged to the cancer group and 421 (72.6 %) to the non-cancer group. More of the patients in the cancer group than those in the non-cancer group had been hospitalized within the prior 2 months (P < 0.001). Leukocytosis was more common in the non-cancer group (P = 0.034), while infection by PCR ribotype 017 strains was more common in the cancer group, with marginal significance (P = 0.07). Recurrence was more frequent in the cancer group (20.4 % vs. 9.5 %, P =0.005) and cancer was an independent risk factor for recurrence of CDI (OR = 2.66, 95 % CI 1.34-5.29, P =0.005). Age also contributed to the recurrence of CDI (OR = 1.03, 95 % CI 1.00-1.06, P =0.026).
Conclusions
Malignancy and age are independent risk factors for recurrence of CDI. Cancer patients require careful observation for recurrence after treatment of CDI.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
- 서울 의과대학 > 서울 외과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.